Artios in-licenses MD Anderson-Shangpharma’s ART inhibitor programme

Pharmaceutical Technology | November 06, 2019

Artios in-licenses MD Anderson-Shangpharma’s ART inhibitor programme
DNA damage response (DDR)-focused company Artios has in-licensed University of Texas MD Anderson and ShangPharma Innovation’s joint ATR inhibitor programme. As a result, Artios will have exclusive rights to research, development, manufacture and commercialise all products globally – the company expects to submit an investigational new drug application for the lead product in the second half of 2020. Financial terms of the agreement were not disclosed. Artios CEO Dr Niall Martin said: “This programme has the potential to be a highly effective DDR-targeted treatment in cancer. “We look forward to advancing the work done by MD Anderson and ShangPharma for the benefit of cancer patients.” MD Anderson vice-president of the therapeutics discovery team Philip Jones added: “Targeting DNA damage repair has the potential to provide an important therapeutic option for many patients in need of new treatments. “We are pleased Artios will leverage its unique expertise in this field to advance this novel therapy toward the clinic to improve outcomes for cancer patients.” ShangPharma CEO Walter Moos continued: “We are pleased to transition this important programme to the capable development team at Artios, and we hope this ultimately provides an impactful therapy for those afflicted with cancer.”

Spotlight

Discover how to partner with Amcor Global Pharma division to design and manufacture the optimal pharma packaging for your patients.

Related News

Red River Biorefinery Now Producing Pharmaceutical Grade (USP) Ethanol for Hand Sanitizers and Disinfectants

Red River Biorefinery | October 06, 2020

The Red River Biorefinery (RRB) announced today that it has expanded production to supply ethanol that meets the U.S. Pharmacopeia (USP) purity and quality standards to the hand sanitizer market. To help meet the increase in global demand for hand sanitizer products due to COVID-19, RRB is now supplying hand sanitizer manufacturers with safe, high-quality ethanol products with one of the lowest carbon footprints available on the market today. It is extremely gratifying to have a local producer supplying safe ingredients for hand sanitizers while providing local jobs to support our communities. The Red River Biorefinery serves a vital role in the region's value-added agricultural, energy, and low carbon economies," said James Leiman, Director of Economic Development and Finance Division for the State of North Dakota.

Read More

PHARMA TECH

FDA Grants Breakthrough Device Designation to Wavegate Corporation's StimuLux

Wavegate Corporation | January 14, 2022

Wavegate Corporation announced that the U.S. Food and Drug Administration has granted Breakthrough Device designation for its StimuLux™ optical reflectometry system for closed-loop adaptive modulation of spinal cord stimulation. The FDA's Breakthrough Device designation is designed to expedite the development and regulatory review of medical devices that are intended to treat serious or life-threatening diseases. To qualify for this designation, preliminary evidence must demonstrate a reasonable expectation that the device will provide improved effectiveness compared to the standard of care. "We are pleased the FDA has granted Breakthrough Device designation for our novel StimuLux™ technology. This underscores the urgent need within our society for more effective treatments of chronic, debilitating pain. We are eager to closely collaborate with the FDA as Wavegate works toward advancing the state of the art." Erich Wolf, MD, PhD, Chief Executive Officer "This designation underscores the urgent need within our society for more effective treatments of chronic, debilitating pain." StimuLux™ is a component of Wavegate Corporation's Ellipse neuromodulation platform which integrates multiple patented technologies which aim to systematically address unmet clinical needs within the neuromodulation industry. About Wavegate Corporation Wavegate Corporation is a privately-held start-up neuromodulation company focused on developing and commercializing a suite of technological innovations including: waveform-independent closed-loop adaptive stimulation, a stimulation paradigm for modulation of both ascending and descending spinal cord pain pathways, new implant geometry for reduced surface contact pressures, rapid lead anchoring, and others.

Read More

Zeblok Computational Announces Partnership with Laufer Center and CEWIT - COVID-19 Drug Discovery

Zeblok Computational, The Laufer Center, CEWIT | July 20, 2020

Zeblok Computational is contributing to the efforts of two groups of researchers at The Laufer Center for Physical and Quantitative Biology, for COVID-19 drug discovery by providing Zeblok’s secure, scalable Supercomputing-as-a-Service platform, employing 128 GPUs from the CEWIT SMART GPU Cluster. The Laufer Center simulations focus on 3 key proteins of the SARS-CoV-2 virus to pinpoint more precisely which drug candidates have the best binding affinity to various protein targets: The RNA-dependent RNA polymerase (which copies the virus inside the cell, thought to be the target of Gilead’s Remdesivir, now in clinical trials) The Protease (which chops up the virus proteins into the right pieces) The spike protein (which is how the virus unlocks the door to enter the cell).

Read More

Spotlight

Discover how to partner with Amcor Global Pharma division to design and manufacture the optimal pharma packaging for your patients.